Merck & Co., Inc. (MRK)
S&P 500 Gains and Losses Today: Merck Stock Plunges on Guidance Cut
Major U.S. equities indexes were mixed for the second straight day as tech stocks lost ground ahead of key earnings reports and a decision on interest rates from the Federal Reserve.
Merck & Co., Inc. (MRK) Q2 2024 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK ) Q2 2024 Earnings Conference Call July 30, 2024 9:00 AM ET Company Participants Peter Dannenbaum - SVP, IR Rob Davis - Chairman and CEO Caroline Litchfield - CFO Dean Li - President of Merck Research Labs Conference Call Participants Chris Schott - JPMorgan Umer Raffat - Evercore Carter Gould - Barclays Tim Anderson - Wolfe Research Steve Scala - TD Cowen Mohit Bansal - Wells Fargo Luisa Hector - Berenberg Dana Graybosch - Leerink Akash Tewari - Jefferies Trung Huynh - UBS Louise Chen - Cantor Chris Shibutani - Goldman Sachs Terence Flynn - Morgan Stanley Evan Seigerman - BMO Capital Markets James Shin - Deutsche Bank Operator Thank you for standing by. Welcome to the Merck & Co. Q2 Sales and Earnings Conference Call [Operator Instructions].
Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View
Merck (MRK) posts better than expected second-quarter results, backed by strong demand for blockbuster cancer drug Keytruda. The stock falls in pre-market trading, likely due to the EPS guidance slash.
Merck Stock Slides on Lowered Adjusted EPS Guidance
Shares of Merck & Co. (MRK) tumbled Tuesday after the pharmaceutical giant cut its full-year adjusted profit guidance.
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Merck & Co. Inc. NYSE: MRK delivered a solid earnings report before the market opened on July 30, 2024. However, the stock was down over 4% in early trading after the company cut its full-year earnings forecast.
Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Merck (MRK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Options Traders Blast 2 Pharma Socks After Earnings
Pharmaceutical giants Merck & Co Inc (NYSE:MRK) and Pfizer Inc (NYSE:PFE) today reported second-quarter results.
Merck (MRK) Q2 Earnings and Revenues Top Estimates
Merck (MRK) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $2.16 per share. This compares to loss of $2.06 per share a year ago.
Merck beats profit and sales expectations amid Keytruda strength, but provides mixed full-year outlook
Shares of Merck & Co. MRK, +2.01% slipped 0.6% in premarket trading Tuesday, after the drug maker reported second-quarter profit and sales that beat expectations, amid strength in sales of cancer treatment Keytruda, while providing a mixed full-year outlook. The company swung to net income of $5.46 billion, or $2.14 a share, from a loss of $5.98 billion, or $2.35 a share, in the same period a year ago.
Merck second quarter tops Street view on strong Keytruda sales
Merck & Co posted higher-than-expected second-quarter results on Tuesday on strong growth of its blockbuster cancer immunotherapy Keytruda, the world's best-selling prescription medicine.
Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda
Merck reported second-quarter revenue and adjusted earnings that topped estimates as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vaccines portfolios and a new cardiovascular drug. The pharmaceutical giant also raised its full-year sales forecast to a range of $63.4 billion to $64.4 billion, however it lowered its adjusted profit guidance to between $7.94 and $8.04 per share.
Germany's Merck raises 2024 sales forecast
Germany's Merck on Friday further its forecast for the group and said it now expects net sales to be between 20.7 billion euros ($22.49 billion) and 22.1 billion euros for 2024.
